Applera Corporation and Beckman Coulter, Inc. jointly announced today that they have entered into a definitive agreement to resolve all outstanding legal disputes between the parties regarding claims to certain Beckman Coulter patented capillary electrophoresis technology and instrumentation technology and Applera's allegations of breach of contract of certain licensed technology. The agreement terms are consistent with those described in the joint announcement of a preliminary agreement made on April 26, 2006.
Genetic Engineering News
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
OssDsign’s Regenerative Cranial Implant Cleared by FDA
The implant’s ceramic component resorbs and is eventually replaced by bone through the healing process.
EMA Blocks Aurobindo Pharma From Supplying Irbesartan
EU authorities have increased scrutiny of Chinese API maker Zhejiang Huahai, the valsartan manufacturer linked to the original contamination of APIs used in blood pressure drugs.
FDAnews Device Daily Bulletin
APPLERA AND BECKMAN COULTER ANNOUNCE FINAL AGREEMENT ON SETTLEMENT
July 5, 2006